SCHEMBL6154264

SCHEMBL6154264

O=C(Nc1nc(-c2ccc(-c3ccccc3)cc2)cs1)c1cc(Cl)ccc1O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RRM1 P23921 1/20 0.60
RRM2B Q7LG56 1/20 0.60
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
RAB9A P51151 3/20 0.59
NPC1 O15118 2/20 0.59
ALDH1A1 P00352 1/20 0.58
MAPT P10636 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
LMNA P02545 1/20 0.57
TMPRSS4 Q9NRS4 1/20 0.54
ABL1 P00519 1/20 0.54
PARP1 P09874 1/20 0.54
TP53 P04637 1/20 0.54
ALOX15 P16050 1/20 0.54
TSHR P16473 1/20 0.54
MAPK1 P28482 1/20 0.54
HTT P42858 1/20 0.54
HSD17B10 Q99714 1/20 0.54
KCNMA1 Q12791 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14886086 0.98 MEN1 (0.61) RRM1RRM2BMEN1KMT2ARAB9A
SCHEMBL15916030 0.87 MEN1 (0.69) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL3278413 0.86 ABL1 (0.63) RRM1RRM2BABL1KCNMA1
SCHEMBL3277061 0.86 MEN1 (0.62) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL3282170 0.86 TMPRSS4 (0.61) MEN1KMT2AMAPTTMPRSS4ABL1
SCHEMBL330472 0.84 KMT2A (0.61) RRM1RRM2BMEN1KMT2ARAB9A
SCHEMBL3279064 0.83 CFTR (0.62) MEN1KMT2AMAPTTMPRSS4ABL1
SCHEMBL3276794 0.82 MAPT (0.61) RAB9AALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL6249035 0.82 SCD (0.74) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL3277194 0.81 TMPRSS4 (0.61) MEN1KMT2AMAPTTMPRSS4KCNMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2005-03-24 US claimed
WO-2003007955-A2 BIPHENYL APURINIC/APYRIMIDINIC SITE ENDONUCLEASE INHIBITORS TO TREAT CANCER CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2003-01-30 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases PTPRS, PTPRJ, PTPRCAP RRM1 2553/4885RRM2B 907/4885MEN1 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.